高龄非禁忌:90岁及以上早期肺癌患者肺立体定向放疗的单中心经验
该单中心前瞻性登记研究分析了2004至2016年间19例90岁及以上早期肺癌患者接受肺立体定向体部放疗(SBRT)的预后与毒性。中位年龄91.6岁,中位随访17.3个月,未观察到3级及以上毒性,2年局部失败率、无进展生存率和总生存率分别为5.6%、48.6%和47.8%。结论认为肺SBRT在该人群安全有效,可考虑作为主要根治手段。
要点
- 90岁及以上早期肺癌患者接受肺SBRT未出现3级及以上毒性。
- 2年局部失败率5.6%,无进展生存率48.6%,总生存率47.8%。
- 中位SBRT方案为50 Gy分5次,连续5天,占47.4%。
核心结论
- 肺SBRT在90岁及以上I期肺癌患者中安全有效,无高级别毒性,可考虑作为主要根治手段。
研究设计与样本
- 单中心经IRB批准的前瞻性肺SBRT数据登记研究,2004至2016年间共1268例肺SBRT病例中识别出19例90岁及以上早期肺癌患者。
主要发现
- 中位年龄91.6岁(范围90-97岁),女性占52.6%,既往吸烟者占78.9%。
- 中位肿瘤大小2.1 cm(范围1.5-5.4 cm),68.4%患者获得组织诊断,腺癌占42.2%,中央型病变占31.6%。
- 中位随访17.3个月,2年局部失败率5.6%,无进展生存率48.6%,总生存率47.8%。
- 未观察到3级及以上毒性。
关键数值与推荐
- 中位SBRT方案为50 Gy分5次,连续5天,共9例(47.4%)采用。
- SBRT前与SBRT后6个月中位FEV1占预计值百分比分别为81.9和84.5,DLCO占预计值百分比分别为66.5和67。
临床怎么用
- 对于90岁及以上早期肺癌患者,肺SBRT未出现高级别毒性且局部控制良好,可考虑作为根治性治疗选择。
局限性
- 单中心回顾性登记资料,样本量仅19例,随访时间有限,结论需谨慎推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report on the patient, tumor, and treatment characteristics of patients aged 90 years or older who were treated with lung stereotactic body radiation therapy (SBRT) for early stage lung cancer and the resulting clinical outcomes. METHODS AND MATERIALS: We surveyed our institutional review board-approved prospective lung SBRT data registry for patients aged 90 years or older who were treated for early stage lung cancer to determine the rates of local failure, progression-free survival, and overall survival as well as treatment-related toxicity. RESULTS: For the 2004 to 2016 time period, 19 patients (of a total of 1268 lung SBRT cases) were identified. The median age at treatment was 91.6 years (range, 90-97 years). Most patients were female (52.6%) and former smokers (78.9%). The median tumor size was 2.1 cm (range, 1.5-5.4 cm). Tissue was obtained for diagnosis in 68.4% of patients, with the predominant histology being adenocarcinoma (42.2%). Six patients (31.6%) had central lesions. The median follow-up for all patients was 17.3 months. The median SBRT schedule was 50 Gy in 5 fractions over 5 consecutive days and was used in 9 cases (47.4%). The median pre-SBRT and 6-month post-SBRT pulmonary testing showed that the forced expiratory volume in one second, as the percent predicted, was 81.9 and 84.5 and the diffusing capacity of the lungs for carbon monoxide, as the percent predicted, was 66.5 and 67, respectively. No grade 3 or higher toxicities were observed. The 2-year rates of local failure, progression-free survival, and overall survival were 5.6%, 48.6%, and 47.8%, respectively. CONCLUSIONS: Lung SBRT appears to be safe and effective in nonagenarians with stage I lung cancer. The absence of high-grade toxicities and mortality warrants its consideration as the primary curative modality in this population.
引用
- Videtic GMM, Woody NM, Reddy CA, et al. Never too old: A single-institution experience of stereotactic body radiation therapy for patients 90 years and older with early stage lung cancer. Pract Radiat Oncol. 2017. PMID: 28867545. doi:10.1016/j.prro.2017.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。